Linden Advisors’s Esperion Therapeutics ESPR Stock Holding History

Linden Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-116,827	Closed	-$1.41M	–	729
2021 Q3	$1.41M	Buy	+116,827	New	+$1.7M	0.01%	405

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Linden Advisors's ESPR Position: Q4 2021 in Review

Linden Advisors sold out of Esperion Therapeutics (ESPR) in Q4 2021, closing a stake of 116,827 shares — an estimated $1.41M sold.

Linden Advisors first reported a position in ESPR in Q3 2021 and held it in 1 quarter. The position peaked at $1.41M in Q3 2021. 133 funds tracked by Wall St. Rank hold ESPR as of Q4 2021.

Linden Advisors reported no remaining Esperion Therapeutics position as of Q4 2021 after selling out during the quarter.
Linden Advisors sold 116,827 Esperion Therapeutics shares in Q4 2021, an estimated $1.41M.
Linden Advisors first reported a position in Esperion Therapeutics in Q3 2021 and held it in 1 quarter.
Linden Advisors's Esperion Therapeutics position peaked at $1.41M in Q3 2021.
133 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2021.

Based on Linden Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.